Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis

Protein Science

Volumn 16, Issue 8, 2007, Pages 1617-1627

  Kruh, Nicole A ^a   Rawat, Richa ^a   Ruzsicska, Béla P ^a   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Enoyl reductase; Fatty acid synthesis; InhA; Isoniazid; Mycobacterium tuberculosis

Indexed keywords

ISONIAZID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ARTICLE; BINDING SITE; BIOSYNTHESIS; CROSS LINKING; ENZYME INHIBITION; GEL FILTRATION; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; ULTRACENTRIFUGATION;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; ISONIAZID; LYSINE; MODELS, MOLECULAR; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PROTEIN CONFORMATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34547576168     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.062749007     Document Type: Article

References (29)

1. Argyrou, A., Vetting, M.W., Aladegbami, B., and Blanchard, J.S. 2006. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol. 13: 408-413.
2. Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K.S., Wilson, T., Collins, D., de Lisle, G., and Jacobs Jr., W.R. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
3. Basso, L.A., Zheng, R., Musser, J.M., Jacobs Jr., W.R., and Blanchard, J.S. 1998. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178: 769-775.
4. Dam, J. and Schuck, P. 2004. Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles. Methods Enzymol. 384: 185-212.
5. Dessen, A., Quemard, A., Blanchard, J.S., Jacobs Jr., W.R., and Sacchettini, J.C. 1995. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267: 1638-1641.
6. Heymann, D.L. 2006. Resistance to anti-infective drugs and the threat to public health. Cell 124: 671-675.
7. Kremer, L., Dover, L.G., Morbidoni, H.R., Vilcheze, C., Maughan, W.N., Baulard, A., Tu, S.C., Honore, N., Deretic, V., Sacchettini, J.C., et al. 2003. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J. Biol. Chem. 278: 20547-20554.
8. Larsen, M.H., Vilcheze, C., Kremer, L., Besra, G.S., Parsons, L., Salfinger, M., Heifets, L., Hazbon, M.H., Alland, D., Sacchettini, J.C., et al. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG, and M. tuberculosis. Mol. Microbiol. 46: 453-466.
9. Marrakchi, H., Laneelle, G., and Quemard, A. 2000. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiol. 146: 289-296.
10. Marrakchi, H., Ducasse, S., Labesse, G., Montrozier, H., Margeat, E., Emorine, L., Charpentier, X., Daffe, M., and Quemard, A. 2002. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. Microbiol. 148: 951-960.
11. Mdluli, K., Sherman, D.R., Hickey, M.J., Kreiswirth, B.N., Morris, S., Stover, C.K., and Barry 3rd, C.E. 1996. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J. Infect. Dis. 174: 1085-1090.
12. Mdluli, K., Slayden, R.A., Zhu, Y., Ramaswamy, S., Pan, X., Mead, D., Crane, D.D., Musser, J.M., and Barry 3rd, C.E. 1998. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 280: 1607-1610.
13. Middlebrook, G. 1952. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am. Rev. Tuberc. 65: 765-767.
14. Odriozola, J.M., Ramos, J.A., and Bloch, K. 1977. Fatty acid synthetase activity in Mycobacterium smegmatis. Characterization of the acyl carrier protein-dependent elongating system. Biochim. Biophys. Acta 488: 207-217.
15. Parikh, S., Moynihan, D.P., Xiao, G., and Tonge, P.J. 1999. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 38: 13623-13634.
16. Quemard, A., Sacchettini, J.C., Dessen, A., Vilcheze, C., Bittman, R., Jacobs Jr., W.R., and Blanchard, J.S. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34: 8235-8241.
17. Rawat, R., Whitty, A., and Tonge, P.J. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc. Natl. Acad. Sci. 100: 13881-13886.
18. Rozwarski, D.A., Vilcheze, C., Sugantino, M., Bittman, R., and Sacchettini, J.C. 1999. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem. 274: 15582-15589.
19. Savvides, S.N., Yeo, H.J., Beck, M.R., Blaesing, F., Lurz, R., Lanka, E., Buhrdorf, R., Fischer, W., Haas, R., and Waksman, G. 2003. VirB11 ATPases are dynamic hexameric assemblies: New insights into bacterial type IV secretion. EMBO J. 22: 1969-1980.
20. Schuck, P. 1998. Sedimentation analysis of noninteracting and self-associating solutes using numerical solutions to the Lamm equation. Biophys. J. 75: 1503-1512.
21. Schuck, P. 2000. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys. J. 78: 1606-1619.
22. Slayden, R.A., Lee, R.E., and Barry 3rd, C.E. 2000. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38: 514-525.
23. Takayama, K., Schnoes, H.K., Armstrong, E.L., and Boyle, R.W. 1975. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J. Lipid Res. 16: 308-317.
24. Veyron-Churlet, R., Guerrini, O., Mourey, L., Daffe, M., and Zerbib, D. 2004. Protein-protein interactions within the fatty acid synthase-II system of Mycobacterium tuberculosis are essential for mycobacterial viability. Mol. Microbiol. 54: 1161-1172.
25. Veyron-Churlet, R., Bigot, S., Guerrini, O., Verdoux, S., Malaga, W., Daffe, M., and Zerbib, D. 2005. The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple specialized elongation complexes interconnected by specific protein-protein interactions. J. Mol. Biol. 353: 847-858.
26. Vilcheze, C., Morbidoni, H.R., Weisbrod, T.R., Iwamoto, H., Kuo, M., Sacchettini, J.C., and Jacobs Jr., W.R. 2000. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 182: 4059-4067.
27. Vilcheze, C., Wang, F., Arai, M., Hazbon, M.H., Colangeli, R., Kremer, L., Weisbrod, T.R., Alland, D., Sacchettini, J.C., and Jacobs Jr., W.R. 2006. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med. 12: 1027-1029.
28. World Health Organization. 2003. Global TB Control Report. World Health Organization, Geneva, Switzerland.
29. Zhang, Y., Heym, B., Allen, B., Young, D., and Cole, S. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: 591-593.